This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Aug. 5, 2013 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its second quarter fiscal year 2013 financial results after the market close on
Monday, August 12, 2013. An investor conference call will follow on the same day at
4:30 p.m. ET.
The conference call will be hosted by
Dan Myers, President and Chief Executive Officer, and
Rick Eiswirth, Chief Operating Officer and Chief Financial Officer.
To participate in the call, please dial (877) 369-6586 (U.S. and
Canada) or (253) 237-1165 (international). A live webcast will be available on the Investor Relations section of the corporate website at
A replay of the conference call will be available beginning
August 12, 2013 at
7:30 p.m. ET and ending on
August 18, 2013 by dialing (855) 859-2056 (U.S. and
Canada) or (404) 537-3406 (international), Conference ID Number: 24162060. A replay of the webcast will be available on the corporate website for one week, through
August 18, 2013.
About Alimera Sciences, Inc.
Alimera Sciences, Inc., based in
Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Presently Alimera is focused on diseases affecting the back of the eye, or retina. Its primary product, ILUVIEN, is the first product to provide a therapeutic effect of up to 36 months for patients with chronic DME considered insufficiently responsive to available therapies.
Investor Contact:ICR, LLCJohn Mills310-954-1105John.Mills@icrinc.com
SOURCE Alimera Sciences, Inc.